Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 20

• 作 者: Yan Wang Li-Qin Zhu
• 机 构: Department of Pharmacy, Tianjin Children’s Hospital, Tianjin 300134, China“,”Department of Pharmacy,
• 出 处: 世界儿科杂志（英文版）
• 发表日期: 2020年3期

Up to now,no antiviral therapeutic regimens with exact efficacy are recommended to be used in children with coronavirus disease 2019 (COVID-19).Interim Guidance for Diagnosis and Treatment (the sixth edition) of COVID-19 [1] only provided potential antiviral treatments in adults.According to the current guidelines for management in adults and children and available resources in antiviral drugs,we herein discussed the pharmaceutical care of the five antiviral treatments (IFN-α,lopinavir/ritonavir,ribavirin,chloroquine diphosphate and arbidol) in children with COVID-19 (Table 1).